| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
S-Diclofenac targets the same pathways as diclofenac, primarily the cyclooxygenase (COX) enzymes, to suppress prostaglandin synthesis. Additionally, the H2S donor moiety provides gastroprotective effects, which are thought to be mediated through various mechanisms including activation of KATP channels and anti-inflammatory effects. It also activates the p53 signaling pathway and inhibits JNK activation.
|
|---|---|
| ln Vitro |
S-Diclofenac significantly suppresses prostaglandin synthesis in vitro. This is a key measure of its anti-inflammatory activity, similar to diclofenac. Its unique property is that it spares the gastric mucosa from injury despite this suppression of prostaglandin synthesis. It also activates the p53 signaling pathway and inhibits the activation of JNK.
|
| ln Vivo |
S-Diclofenac has demonstrated in vivo activity, primarily characterized by its ability to suppress prostaglandin synthesis while protecting the gastric mucosa. This suggests it is effective in animal models of inflammation and pain, with a reduced risk of gastrointestinal side effects compared to diclofenac. Its H2S-donating properties contribute to its gastroprotective effects.
|
| Enzyme Assay |
The in vitro activity of S-Diclofenac is assessed by measuring its ability to inhibit prostaglandin synthesis. This is typically done using cell-based or enzyme-based assays that measure the production of prostaglandins. Its effect on the p53 signaling pathway and JNK activation can also be assessed in cell-based assays by Western blotting.
|
| Cell Assay |
Cell-based assays are used to evaluate the activity of S-Diclofenac. Its ability to suppress prostaglandin synthesis can be measured in cultured cells, such as macrophages or other inflammatory cells. Its effects on cell signaling pathways, such as p53 and JNK, can also be studied in various cell lines.
|
| Animal Protocol |
S-Diclofenac has been studied in animal models to evaluate its anti-inflammatory and gastroprotective effects. In these studies, the compound is typically administered orally, and its effects on inflammation (e.g., carrageenan-induced paw edema) and gastric mucosal injury are assessed. The results demonstrate that it is effective in reducing inflammation while protecting the stomach.
|
| ADME/Pharmacokinetics |
S-Diclofenac has a molecular weight of 504.47 and a molecular formula of C23H15Cl2NO2S3. It is a hybrid molecule of an H2S donor and the NSAID diclofenac. It is also known as ACS-15 and ATB-337. It is a crystalline solid, soluble in DMF (20 mg/ml) and DMSO (10 mg/ml). Its purity is ≥98%.
|
| Toxicity/Toxicokinetics |
S-Diclofenac is a research compound designed to have a better safety profile than diclofenac. Its toxicity profile is expected to be improved due to the gastroprotective effects of the H2S donor moiety. However, as with any NSAID, there is potential for other side effects. Comprehensive toxicology studies would be required.
|
| References | |
| Additional Infomation |
S-Diclofenac (CAS#: 912758-00-0) is a hybrid molecule of a hydrogen sulfide (H2S) donor and the NSAID diclofenac, also known as ACS-15 and ATB-337. It significantly suppresses prostaglandin synthesis while sparing the gastric mucosa from injury. It activates the p53 signaling pathway and inhibits JNK activation. S-Diclofenac is a research tool for studying inflammation and pain with reduced gastrointestinal toxicity.
|
| Molecular Formula |
C23H15NO2S3CL2
|
|---|---|
| Molecular Weight |
504.4717
|
| Exact Mass |
502.964
|
| CAS # |
912758-00-0
|
| PubChem CID |
11948307
|
| Appearance |
Reddish brown to red solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
640.7±65.0 °C at 760 mmHg
|
| Flash Point |
341.3±34.3 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.756
|
| LogP |
7.18
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
674
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BRDUXOHVEZVAHI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H15Cl2NO2S3/c24-17-5-3-6-18(25)23(17)26-19-7-2-1-4-15(19)12-21(27)28-16-10-8-14(9-11-16)20-13-22(29)31-30-20/h1-11,13,26H,12H2
|
| Chemical Name |
[4-(5-sulfanylidenedithiol-3-yl)phenyl] 2-[2-(2,6-dichloroanilino)phenyl]acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~198.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9823 mL | 9.9114 mL | 19.8228 mL | |
| 5 mM | 0.3965 mL | 1.9823 mL | 3.9646 mL | |
| 10 mM | 0.1982 mL | 0.9911 mL | 1.9823 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
